Agios Pharmaceuticals Inc (STU:8AP)
€ 34.2 -3 (-8.06%) Market Cap: 1.93 Bil Enterprise Value: 1.03 Bil PE Ratio: 3.01 PB Ratio: 1.20 GF Score: 50/100

Q1 2024 Agios Pharmaceuticals Inc Earnings Call Transcript

May 02, 2024 / 12:00PM GMT
Release Date Price: €31.4 (+3.29%)
Operator

Good morning, and welcome to Agios first Quarter 2024 conference call. (Operator Instructions) I would now like to turn the call over to Chris Taylor, Vice President, Investor Relations and Corporate Communications for Agios. Please begin. I would now like to turn the call over to Chris Taylor, Vice President, Investor Relations and Corporate Communications for Agios. Please begin.

Christopher Taylor
Agios Pharmaceuticals Inc - Vice President, Investor Relations and Corporate Communications

Thank you, operator. Good morning, everyone, and welcome to Agios' conference call and webcast to discuss Q1 2024 financial results and recent business highlights. You can access slides for today's call by going to the Investors section of our website, agios.com. On today's call, I'm joined by our Chief Executive Officer, Brian Goff Doctor; Sarah Huyns, Chief Medical Officer and Head of R&D; Sveta Milanova, our Chief Commercial Officer; and Cecilia Jones, Chief Financial Officer.

Before we get started, I would like to remind everyone that some of the statements

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot